The COVID-19 pandemic derailed plans for companies worldwide last year, but Eli Lilly adapted by developing medicines against the novel coronavirus—to the tune of $ 871 million in antibody revenue for Q4—while still pushing sales of its newer meds. Now, CEO David Ricks is reaping the rewards with a pay package that could place him… Read More »
The Washington PostGetty Images Brands, gyms, and athletes are ending their affiliations with CrossFit after CEO Greg Glassman tweeted an insensitive remark about George Floyd and the current Black Lives Matter protests happening around the country. On June 4, the Institute for Health Metrics and Evaluation tweeted a statement which called racism and discrimination “critical… Read More »
Katie BuckleitnerGetty Images If you’re even the tiniest bit into astrology, you know your Sun sign. You might also know that each sign has an element (fire, water, earth, and air). In astrology, the signs are also broken down into three different qualities—cardinal, fixed, and mutable. The four cardinal signs are Aries, Cancer, Libra, and… Read More »
AstraZeneca warned of slowing China growth after it lost a major government procurement deal for Crestor to a generic drugmaker. BeiGene’s CEO nabbed a $ 15 million special equity award in 2018 and ranked as biopharma’s second-highest-paid exec for the year. China’s Kangmei Pharma saw shares plummet on news that its shares could be delisted after a $ 4.4 billion accounting “error.” 1.… Read More »
SAN FRANCISCO—Bristol-Myers Squibb and Celgene sent 2019’s first big shockwave throughout pharma with last week’s $ 74 billion megamerger announcement. And they immediately touched off questions about the deal: Analysts called it too expensive, not to mention risky on the patent side and pipeline, too. But even as market watchers continued to offer up their reservations on… Read More »